Monacolins from fermented red rice could be banned in food supplements in the European Union. On 13 May 2026, the SCoPAAF approved a European Commission proposal aimed at banning their use. This is a significant update for manufacturers, distributors and companies in the nutraceutical sector. However, the ban is not yet definitively in force: the…
The disclosure obligations on unsold products introduce new requirements for European businesses under the Ecodesign for Sustainable Products Regulation (ESPR). The provisions establish how the economic operators concerned must report information on unsold consumer products they have discarded, with the aim of increasing transparency and helping to prevent the destruction of goods. The new provisions…
Manufacturing site of FarmaImpresa has been officially registered with the Supreme Board of Drugs & Medical Appliances FarmaImpresa’s manufacturing site has been officially registered with the Supreme Board of Drugs & Medical Appliances (SBDMA) of the Ministry of Health and Environment of the Republic of Yemen. The authorization confirms the technical and production capability of…
Regulatory update on red yeast rice monacolins in food supplements. The European Commission is evaluating a possible total ban, with transitional periods of 6 or 12 months. Analysis of timelines, regulatory implications, EFSA’s role and impact on nutraceutical companies. Red yeast rice monacolins are once again at the center of the European regulatory debate. In…
Crucial Judgment from the EU Court of Justice on Health Claims for Botanical Substances A recent and significant ruling by the Court of Justice of the European Union (EU) is redefining the regulatory landscape for the use of health claims related to botanical substances in food products and food supplements. In particular, the decision in…
Gruppo FarmaImpresa at the Top of European Quality: Maximum Safety for Gynecologic Well-Being The EU Regulation 2017/745 (MDR) is Europe’s most stringent framework for manufacturing and marketing medical devices. It raises the bar on safety, quality, and traceability, introducing far stricter requirements than previous directives. For Gruppo FarmaImpresa, obtaining MDR certification for the Class IIb…
Navigating the Future of Medical Devices: A Deep Dive into the European Commission’s MDR Revision and Industry Proposals for a More Efficient and Innovative Landscape The European Commission has officially announced the launch of the Medical Device Regulation (MDR) revision, a welcome development for the industry. This initiative, communicated by European Commissioner for Health, Olivér…
MDR Transition Extended Beyond 2024: Ongoing Market Access for Our Nasal Kits The MDR (Medical Device Regulation), in force since May 2017 and fully applicable from May 2021, governs medical devices across Europe. Thanks to the extended transition timelines, devices compliant with the MDD Directive can remain on the market until December 31, 2027, for…
Ensured Continuity: Our Osteoarticular Line Is Ready for the MDR Future The Medical Device Regulation (MDR), in force since May 2017 and fully applicable as of May 2021, governs medical devices in Europe. Thanks to deadline extensions, devices compliant with the previous MDD Directive may continue to be marketed until December 31, 2027 for Class…
A crucial EU ruling (Case C-589/23) redefines the distinction between medical devices and medicinal products, clarifying when a substance—like D-mannose—exerts a pharmacological action under Directive 2001/83/EC The boundary between “medicinal product” and “medical device” is often subject to divergent interpretations in European markets, especially for so-called borderline products that do not clearly fall under one…